NeOnc Insider Buying Continues Ahead of NEO100 Data and November 17 FDA Meeting
By Ben Hansel, Senior Financial Editor 247MarketNews
DENVER, Colo. (247MarketNews) — NeOnc Technologies Holdings (NASDAQ:NTHI) is approaching an important two-week period, with additional CEO share purchases, renewed analyst support and two upcoming clinical milestones bringing the small-cap biotechnology company back into focus.
CEO Amir Heshmatpour purchased another 70,000 shares for approximately $230,510 in open-market transactions on November 5 and 6, according to his latest SEC Form 4. The purchases comprised 30,000 shares at a weighted average of $3.167 and 40,000 at $3.3875.
His direct ownership increased to 3.253 million shares. Including holdings through affiliated entities, his reported beneficial ownership is approximately 7.77 million shares.
The purchases follow an earlier announcement that Heshmatpour and fellow insider Thomas C. Chen acquired a combined 160,016 shares for approximately $629,000 following the company's positive NEO100 Phase 2a results. The latest transactions bring additional personal capital into the stock ahead of further clinical disclosures.
Analyst coverage provides another point of interest; Roth MKM reiterated its Buy rating and $20 price target on November 6, according to market analyst tracking data. Maxim Group also maintained a $20 target on November 5, while BTIG's September target was $15.
At the November 6 closing price of $3.49, Roth's target represents a substantial valuation gap. Whether that gap can narrow depends largely on clinical evidence and the company's ability to finance further development.
NeOnc's principal near-term catalyst is NEO100, an intranasal treatment candidate for recurrent IDH1-mutant high-grade glioma. In August, the company reported that its 24-patient Phase 2a study achieved six-month progression-free survival of 48.9%, against a prespecified 20% historical benchmark (p=0.0047). Median overall survival was reported at 26.1 months.
On November 13, NeOnc plans to present updated NEO100 Phase 1/2a findings and Phase 1 safety and early activity data for its second candidate, NEO212, at the Society for Neuro-Oncology annual meeting in Philadelphia.
A further milestone follows on November 17, when the company is scheduled to meet with the FDA for an End-of-Phase 1 discussion concerning NEO212. The meeting is intended to address proposed Phase 2 design, patient selection, endpoints and potential regulatory pathways.
For NEO100, NeOnc submitted requests in October for separate FDA discussions covering its proposed accelerated approval strategy, confirmatory Phase 3 design and manufacturing requirements.
Short interest is another part of the trading picture, as the October 15 reporting period showed 876,682 shares sold short, equivalent to approximately 5.3 days of average trading volume under one market-data calculation.
The next two weeks should provide investors with more information about both drug candidates and the regulatory path ahead, while Heshmatpour's continued purchases and the analyst targets demonstrate confidence among certain market participants.
About 247MarketNews
In today's fast-moving markets, visibility is everything and 247MarketNews provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 247MarketNews delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact [email protected] to discuss how 247MarketNews can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247MarketNews is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247MarketNews highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
About the Author
Ben Hansel is a financial and business writer with a background in business, sales, and finance. He graduated from the University of Texas at El Paso. His professional and educational background informs his coverage of financial markets, corporate developments, economic trends and the broader forces shaping the market.
CONTACT:
247MarketNews
[email protected]
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.